Nymox Pharmaceutical Stock Forecast, Price & News

Wall Street analysts have given Nymox Pharmaceutical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nymox Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Nymox Pharmaceutical.

Nymox Pharmaceutical Co. (NASDAQ:NYMX) announced its quarterly earnings results on Friday, August, 13th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter.
View Nymox Pharmaceutical's earnings history.

Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NYMX shares have decreased by 17.5% and is now trading at $1.89.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Nymox Pharmaceutical include Aspira Women's Health (AWH), OncoCyte (OCX), Lucira Health (LHDX), Quotient (QTNT), MyMD Pharmaceuticals (MYMD), VolitionRx (VNRX), Achieve Life Sciences (ACHV), ImmuCell (ICCC), Biomerica (BMRA), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), ARCA biopharma (ABIO), StageZero Life Sciences (GNWSD), Global WholeHealth Partners (GWHP) and StageZero Life Sciences (GNWSF).
View all of NYMX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Nymox Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.39%), Ergoteles LLC (0.23%), Tibra Equities Europe Ltd (0.18%), Morgan Stanley (0.09%), Morgan Stanley (0.09%) and Goldman Sachs Group Inc. (0.06%).
View institutional ownership trends for Nymox Pharmaceutical.

NYMX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, JPMorgan Chase & Co., Bank of America Corp DE, and Parametric Portfolio Associates LLC.
View insider buying and selling activity for Nymox Pharmaceutical or view top insider-selling stocks.

NYMX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, Tibra Equities Europe Ltd, Boothbay Fund Management LLC, Goldman Sachs Group Inc., Morgan Stanley, Morgan Stanley, and Simplex Trading LLC.
View insider buying and selling activity for Nymox Pharmaceutical or or view top insider-buying stocks.

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NYMX stock can currently be purchased for approximately $1.89.

Nymox Pharmaceutical has a market capitalization of $155.70 million.

Nymox Pharmaceutical employs 3 workers across the globe.

The official website for Nymox Pharmaceutical is www.nymox.com.

Nymox Pharmaceutical is headquartered at BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2.

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The biopharmaceutical company can be reached via phone at (800) 936-9669 or via email at [email protected].